Poliovirus antigen type 1 (PV1 antigen)

Poliovirus antigen types 1, 2, and 3 refer to the three distinct serotype-defining surface epitopes (antigenic forms) present on the capsids of poliovirus. The term is not itself a canonical target molecule (such as a receptor or enzyme), but rather refers to immunodominant antigenic sites found on the viral capsid proteins—especially regions of VP1, VP2, and VP3 proteins—which elicit serotype-specific neutralizing antibody responses[1][2][3]. These capsid antigenic sites are the basis for the trivalent structure of poliovirus vaccines and are the determinants for immune protection or susceptibility to each type. Each serotype is antigenically distinct, such that infection or vaccination with one serotype does not confer immunity against the others[6]. The principal clinical relevance is in vaccine design, immunogenicity studies, and surveillance for vaccine- or infection-derived antibody responses[1][4][6]. While these antigens are not therapeutic "targets" in the sense of being bound by drugs, they are critical for the mechanism of action of neutralizing antibodies and vaccines[1][4][6]. There is no single protein or receptor called "Poliovirus antigen types 1/2/3"; this phrase refers generally to the antigenic determinants defining the three groups within human poliovirus[6]. The phrase "Poliovirus antigen types 1/2/3" is not a standard, singular molecular entity but an umbrella description of the three serotype-specific antigenic forms used in immunology and vaccine science[6]. The actual molecular targets are specific antigenic sites (epitopes) on the surface of the viral capsid, especially on the proteins VP1, VP2, and VP3[1][2][4][5].

Other names

Poliovirus antigen type 1Poliovirus antigen type 2Poliovirus antigen type 3PV1 antigenPV2 antigenPV3 antigen

Neutralization (by antibodies, preventing cell entry)